Quantitative assessment of minimal residual disease for monitoring of paediatric patients with relapsed/refractory anaplastic large‐cell lymphoma treated with brentuximab vedotin: A case series-Reference-Cited by-同舟云学术

Quantitative assessment of minimal residual disease for monitoring of paediatric patients with relapsed/refractory anaplastic large‐cell lymphoma treated with brentuximab vedotin: A case series

Published:2023-10-11 Issue:1 Volume:204 Page:352-355
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Contarini Giorgia¹²,Carraro Elisa¹,Lovisa Federica²,Martire Gaia¹²,Lo Nigro Luca³^ORCID,Sala Alessandra⁴,Pillon Marta¹^ORCID,Mussolin Lara¹²^ORCID

Affiliation:

1. Maternal and Child Health Department Pediatric Hematology, Oncology and Stem Cell Transplant Center University of Padua Padua Italy

2. Pediatric Research Institute “Città della Speranza” Padua Italy

3. Center of Pediatric Hematology‐Oncology Azienda Policlinico—San Marco Catania Italy

4. Department of Pediatric Hematology Oncology, Fondazione IRCCS San Gerardo dei Tintori, Centro Maria Letizia Verga University of Milano‐Bicocca Monza Italy

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19151

Reference15 articles.

1. A population-based study of pediatric anaplastic large cell lymphoma

2. Pediatric anaplastic large cell lymphoma—a review;Tole S;Oncol Hematol Rev,2018

3. Impact of the Methotrexate Administration Dose on the Need for Intrathecal Treatment in Children and Adolescents With Anaplastic Large-Cell Lymphoma: Results of a Randomized Trial of the EICNHL Group

4. Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial

5. Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents